A novel Bursin-like peptide as a potential virus inhibitor and immunity regulator in SPF chickens infected with recombinant ALV.
ALV
Bursin-like peptide
Growth
Immunity suppression
Virus inhibitor
Journal
BMC veterinary research
ISSN: 1746-6148
Titre abrégé: BMC Vet Res
Pays: England
ID NLM: 101249759
Informations de publication
Date de publication:
10 Dec 2019
10 Dec 2019
Historique:
received:
04
07
2019
accepted:
25
11
2019
entrez:
12
12
2019
pubmed:
12
12
2019
medline:
14
4
2020
Statut:
epublish
Résumé
Avian leukosis viruses (ALVs) are important contagious suppressive factors of chicken immunity and growth performance, resulted in enormous economic loss. Although virus eradication programs are applied in breeder flocks, ALVs are still widespread globally. Therefore, other valuable adjunct to reduce the negative effect of ALVs should be considered. Bursin-like peptide (BLP) showed remarkable immunomodulatory effects, whereas their influence on ALV-infected avian groups has not been reported. Here, a designed hybrid BLP was expressed in E. coli. The purified BLP was injected subcutaneously weekly in SPF chickens congenitally infected with a natural ALV strain. Then the influences of this BLP on the growth performance, immune response and virus titer of ALV-infected chickens were determined. This BLP injection significantly improved the body weights of ALV-infected birds (P < 0.05). BLP injection significantly enhanced organ index in the BF in ALV-infected birds (P < 0.05). The weekly injection of BLP significantly lengthened the maintenance time of antibodies against Newcastle disease virus (NDV) attenuated vaccine of ALV-infected birds (P < 0.05) and boosted the antibody titer against avian influenza virus (AIV) H This is the first report investigating the influence of BLP on the growth and immunity performance of chickens infected by ALV. It also is the first report about the antiviral effect of BLP in vivo and in vitro. This BLP expressed in E. coli showed potential as a vaccine adjuvant, growth regulator and antiretroviral drug in chickens to decrease the negative effects of ALV infection.
Sections du résumé
BACKGROUND
BACKGROUND
Avian leukosis viruses (ALVs) are important contagious suppressive factors of chicken immunity and growth performance, resulted in enormous economic loss. Although virus eradication programs are applied in breeder flocks, ALVs are still widespread globally. Therefore, other valuable adjunct to reduce the negative effect of ALVs should be considered. Bursin-like peptide (BLP) showed remarkable immunomodulatory effects, whereas their influence on ALV-infected avian groups has not been reported. Here, a designed hybrid BLP was expressed in E. coli. The purified BLP was injected subcutaneously weekly in SPF chickens congenitally infected with a natural ALV strain. Then the influences of this BLP on the growth performance, immune response and virus titer of ALV-infected chickens were determined.
RESULTS
RESULTS
This BLP injection significantly improved the body weights of ALV-infected birds (P < 0.05). BLP injection significantly enhanced organ index in the BF in ALV-infected birds (P < 0.05). The weekly injection of BLP significantly lengthened the maintenance time of antibodies against Newcastle disease virus (NDV) attenuated vaccine of ALV-infected birds (P < 0.05) and boosted the antibody titer against avian influenza virus (AIV) H
CONCLUSIONS
CONCLUSIONS
This is the first report investigating the influence of BLP on the growth and immunity performance of chickens infected by ALV. It also is the first report about the antiviral effect of BLP in vivo and in vitro. This BLP expressed in E. coli showed potential as a vaccine adjuvant, growth regulator and antiretroviral drug in chickens to decrease the negative effects of ALV infection.
Identifiants
pubmed: 31823780
doi: 10.1186/s12917-019-2192-2
pii: 10.1186/s12917-019-2192-2
pmc: PMC6902579
doi:
Substances chimiques
Oligopeptides
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
447Subventions
Organisme : Discipline Development Grant from College of Animal Sciences FAFU
ID : 2018DK008
Organisme : Natural Science Foundation of China
ID : 31402227
Références
Vaccine. 2000 Mar 17;18(18):1886-92
pubmed: 10699337
Science. 1986 Feb 28;231(4741):997-9
pubmed: 3484838
J Control Release. 2017 Jun 28;256:114-120
pubmed: 28457895
J Int AIDS Soc. 2014 Nov 02;17(4 Suppl 3):19581
pubmed: 25394088
BMC Public Health. 2015 Mar 07;15:226
pubmed: 25886530
Front Immunol. 2017 Dec 22;8:1856
pubmed: 29312337
Biotechnol Ther. 1994-1995;5(3-4):163-70
pubmed: 8608325
Curr Top Microbiol Immunol. 2017;407:65-82
pubmed: 28688086
Cell Immunol. 2014 Nov-Dec;292(1-2):57-64
pubmed: 25282449
Vet Microbiol. 2017 Jun;205:34-38
pubmed: 28622858
Mol Immunol. 2015 Mar;64(1):106-11
pubmed: 25438822
Avian Pathol. 1986;15(1):63-74
pubmed: 18766505
Vet Immunol Immunopathol. 2008 Apr 15;122(3-4):265-74
pubmed: 18191231
Microb Pathog. 2015 Jan;78:7-13
pubmed: 25450885
Science. 1976 Jul 23;193(4250):319-21
pubmed: 180600
Avian Pathol. 2002 Feb;31(1):59-72
pubmed: 12425793
Poult Sci. 1994 Jul;73(7):1082-6
pubmed: 7937469
Vet Microbiol. 1989 Jan;19(1):53-64
pubmed: 2538023
Avian Pathol. 2001 Dec;30(6):641-54
pubmed: 19184958
Biotechnol Lett. 2014 Jul;36(7):1431-7
pubmed: 24652544
Virus Res. 2018 Mar 15;248:63-70
pubmed: 29481814
Mar Drugs. 2017 Nov 03;15(11):null
pubmed: 29099785
Immunology. 1977 Mar;32(3):271-4
pubmed: 557452
Arch Virol. 2018 Apr;163(4):987-995
pubmed: 29327234
Viral Immunol. 2018 Jul/Aug;31(6):407-416
pubmed: 29698128
Avian Pathol. 2012;41(1):11-9
pubmed: 22845317
Nucleic Acids Res. 2011 Aug;39(14):5879-92
pubmed: 21459854